Sarcoma trials in Canada

In Canada 38 Also abroad 605

33 of 38 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Where
Halifax, Hamilton, Montreal, Toronto, Trois-Rivières, Winnipeg
Age
18 years and over
People
348 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Where
Montreal
Age
18 years and over
People
400 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01
Phase 3Taking people
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Where
Calgary, Edmonton, Hamilton, Ottawa, Québec, Toronto, Vancouver, Winnipeg
Age
18 years and over
People
365 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT06422806
Phase 1/2Taking people
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Where
Toronto
Age
2 years to 30 years
People
60 worldwide
Run by
Jazz Pharmaceuticals
See details and how to joinNCT05734066
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Halifax, Montreal, Toronto
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Calgary, Montreal, Toronto
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 1Taking people
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Where
Calgary, Montreal, Ottawa, Toronto
Age
15 years and over
People
30
Run by
Canadian Cancer Trials Group
See details and how to joinNCT07297667
Phase 2Not yet taking people in Canada
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial
Where
Toronto
Age
18 years and over
People
46
Run by
University Health Network, Toronto
See details and how to joinNCT07820033
No phaseTaking people
Evaluating the Use of Educational Videos in Newly Diagnosed Patients in a Medical Oncology Sarcoma Clinic
Where
Toronto
Age
18 years and over
People
100
Run by
Mount Sinai Hospital, Canada
See details and how to joinNCT06805773
Phase 1Taking people
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Where
Montreal
Age
18 years and over
People
180 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07261631
Phase 3Taking people
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Where
London, Montreal, Ottawa, Toronto, Vancouver
Age
18 years and over
People
250 worldwide
Run by
European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04031677
Phase 1/2Taking people
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Where
Montreal
Age
Up to 30 years
People
104 worldwide
Run by
Milton S. Hershey Medical Center
See details and how to joinNCT06541262
Phase 1/2Taking people
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
Where
Montreal, Toronto
People
64 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07602777
Phase 1Taking people
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
Where
Toronto
Age
18 years and over
People
405 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06884618 · EU 2024-519622-20-00
Phase 1/2Taking people
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Where
Calgary, Edmonton, Montreal, Ottawa
Age
Up to 25 years
People
75 worldwide
Run by
Turning Point Therapeutics, Inc.
See details and how to joinNCT04094610 · EU 2023-506464-14-00
Phase 2Taking people
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
Where
Toronto, Vancouver
Age
18 years and over
People
50
Run by
British Columbia Cancer Agency
See details and how to joinNCT04273061
Phase 3Taking people
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Where
Calgary, Edmonton, Halifax, Montreal, Sherbrooke
Age
Up to 50 years
People
62 worldwide
Run by
Children's Oncology Group
See details and how to joinNCT05235165
Phase 3Taking people
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Where
Calgary, Edmonton, Halifax, Montreal, Québec, Sherbrooke, Toronto, Vancouver, Winnipeg
Age
Up to 21 years
People
205 worldwide
Run by
Children's Oncology Group
See details and how to joinNCT05304585
Phase 3Taking people
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Where
Montreal
Age
Up to 50 years
People
342 worldwide
Run by
Children's Oncology Group
See details and how to joinNCT07466316
Phase 3Taking people
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
Where
Toronto
Age
18 years and over
People
333 worldwide
Run by
Intensity Therapeutics, Inc.
See details and how to joinNCT06263231 · EU 2024-512423-36-00
No phaseTaking people
Circulating Tumor DNA in Soft Tissue Sarcoma
Where
Toronto
Age
18 years and over
People
40
Run by
University Health Network, Toronto
See details and how to joinNCT03818412
Phase 2Taking people
A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas
Where
Toronto
Age
18 years and over
People
20
Run by
University Health Network, Toronto
See details and how to joinNCT07014137
Phase 1/2Taking people
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Where
Toronto, Vancouver
Age
18 years and over
People
252 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07223047
Phase 1/2Taking people
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Where
Edmonton, Ontario, Ottawa, Toronto, Vancouver
Age
12 years and over
People
500 worldwide
Run by
Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00
Phase 1/2Taking people
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Where
Montreal, Toronto, Vancouver
Age
12 months to 30 years
People
90 worldwide
Run by
St. Jude Children's Research Hospital
See details and how to joinNCT04901702